Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease.


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
07 Mar 2022
Historique:
entrez: 16 3 2022
pubmed: 17 3 2022
medline: 17 3 2022
Statut: epublish

Résumé

Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly protective vaccines against coronaviruses that cause severe disease, for anticipating novel pandemic-causing viruses, and to respond more effectively to SARS-CoV-2 variants. The emergence of the Omicron variant of SARS-CoV-2 has illustrated the limitations of solely targeting the receptor binding domain (RBD) of the envelope Spike (S)-protein. Here, we isolated a large panel of broadly neutralizing antibodies (bnAbs) from SARS-CoV-2 recovered-vaccinated donors that target a conserved S2 region in the fusion machinery on betacoronavirus spikes. Select bnAbs show broad

Identifiants

pubmed: 35291291
doi: 10.1101/2022.03.04.479488
pmc: PMC8923106
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI157155
Pays : United States
Organisme : NIAID NIH HHS
ID : R61 AI161818
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI145372
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA260543
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007384
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : INV-004923
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

Immunity. 2015 Nov 17;43(5):959-73
pubmed: 26588781
Nature. 2021 Sep;597(7874):97-102
pubmed: 34261126
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
PLoS Pathog. 2019 Jun 13;15(6):e1007819
pubmed: 31194843
Sci Transl Med. 2022 Jan 19;14(628):eabl7430
pubmed: 34941423
N Engl J Med. 2021 Jan 21;384(3):289-291
pubmed: 33471984
J Virol. 2005 Dec;79(23):14909-22
pubmed: 16282490
J Infect Dis. 2018 Jul 2;218(3):347-354
pubmed: 29506129
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Virology. 2018 Apr;517:98-107
pubmed: 29277291
Science. 2021 Aug 13;373(6556):818-823
pubmed: 34016740
Cell Host Microbe. 2020 May 13;27(5):695-698
pubmed: 32407707
Science. 2013 May 10;340(6133):711-6
pubmed: 23539181
Bioinformatics. 2007 Nov 1;23(21):2947-8
pubmed: 17846036
Cell. 2020 Nov 12;183(4):1070-1085.e12
pubmed: 33031744
Cell. 2021 Aug 5;184(16):4203-4219.e32
pubmed: 34242577
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Sci Immunol. 2021 Oct 15;6(64):eabj2901
pubmed: 34652962
Cell. 2020 Nov 25;183(5):1367-1382.e17
pubmed: 33160446
Sci Transl Med. 2022 Feb 16;14(632):eabi5735
pubmed: 34914540
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Front Immunol. 2021 Apr 28;12:675679
pubmed: 33995420
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell Rep. 2021 May 11;35(6):109109
pubmed: 33932326
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Immunol Rev. 2017 Jan;275(1):5-10
pubmed: 28133795
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Science. 2021 Feb 19;371(6531):759
pubmed: 33602830
Science. 2021 Feb 19;371(6531):823-829
pubmed: 33495307
Cell Rep. 2021 Dec 21;37(12):110188
pubmed: 34936878
Nat Rev Immunol. 2013 Sep;13(9):693-701
pubmed: 23969737
Nature. 2021 Sep;597(7874):103-108
pubmed: 34280951
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Cell Rep. 2022 Jan 11;38(2):110210
pubmed: 34971573
Nature. 2019 Feb;566(7744):398-402
pubmed: 30760926
PeerJ. 2020 Feb 26;8:e8584
pubmed: 32149022
N Engl J Med. 2022 Jan 27;386(4):297-299
pubmed: 34910863
Viruses. 2021 Apr 07;13(4):
pubmed: 33916927
PLoS One. 2015 Jun 26;10(6):e0131451
pubmed: 26115403
Nat Commun. 2021 Mar 17;12(1):1715
pubmed: 33731724
J Virol. 2015 Oct 14;90(1):76-91
pubmed: 26468542
Sci Transl Med. 2022 Jan 26;14(629):eabj7125
pubmed: 34726473
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Science. 2021 Sep 03;373(6559):1109-1116
pubmed: 34344823
Nature. 2021 Jun;594(7864):553-559
pubmed: 33971664
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Microbiol. 2016 Nov 28;2:16226
pubmed: 27892925
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Nat Struct Mol Biol. 2021 Jun;28(6):478-486
pubmed: 33981021
J Immunol. 2017 Nov 1;199(9):3369-3380
pubmed: 28978691
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Sci Transl Med. 2021 Jun 30;13(600):
pubmed: 34103407
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33211088
Cell Rep. 2021 Nov 2;37(5):109929
pubmed: 34710354
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Nature. 2021 Feb;590(7846):386-388
pubmed: 33558746
J Virol. 2012 Jan;86(2):884-97
pubmed: 22072787
Science. 2019 Dec 6;366(6470):
pubmed: 31672916
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Cell Rep. 2021 Jul 13;36(2):109353
pubmed: 34237283
Nature. 2019 Feb;566(7744):393-397
pubmed: 30664748
Nat Commun. 2019 Feb 7;10(1):628
pubmed: 30733445
Cell Rep. 2019 May 21;27(8):2426-2441.e6
pubmed: 31116986
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
JAMA. 2021 Apr 6;325(13):1261-1262
pubmed: 33571363
Curr Opin Immunol. 2018 Aug;53:143-151
pubmed: 29775847
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Nat Commun. 2021 May 19;12(1):2938
pubmed: 34011939

Auteurs

Panpan Zhou (P)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Ge Song (G)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Wan-Ting He (WT)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Nathan Beutler (N)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Longping V Tse (LV)

Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

David R Martinez (DR)

Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Alexandra Schäfer (A)

Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Fabio Anzanello (F)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Peter Yong (P)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Linghang Peng (L)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Katharina Dueker (K)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Rami Musharrafieh (R)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Sean Callaghan (S)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Tazio Capozzola (T)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Meng Yuan (M)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Hejun Liu (H)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Oliver Limbo (O)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

Mara Parren (M)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Elijah Garcia (E)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Stephen A Rawlings (SA)

Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.

Davey M Smith (DM)

Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.

David Nemazee (D)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Joseph G Jardine (JG)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

Ian A Wilson (IA)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Yana Safonova (Y)

Department of Computer Science, Johns Hopkins University, Baltimore, MD 21218, USA.

Thomas F Rogers (TF)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.

Ralph S Baric (RS)

Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Departments of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Lisa E Gralinski (LE)

Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Dennis R Burton (DR)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA.

Raiees Andrabi (R)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Classifications MeSH